Actithera appoints Steven Kelly as CEO and strengthens Board with Briggs Morrison as Chair and John Crowley as Independent Director. Learn More
Actithera appoints Steven Kelly as CEO and strengthens Board with Briggs Morrison as Chair and John Crowley as Independent Director. Learn More
Our molecular design approaches result in Best-In-Class compounds, some of which are currently being prepared for clinical trials in cancer patients.
Radioligand therapy is truly personalized —patients are imaged first, and only those with sufficient tracer uptake receive the appropriate level of treatment.
RLT is generally better tolerated than traditional cancer treatments, and at Actithera, we raise the bar even further by designing molecules that concentrate more in tumors while sparing healthy tissues.
Our proprietary chemistry enables us to match the half-life of long-lived radionuclides with the residence time of our compounds in tumors. This alignment allows for effective treatment with fewer therapy cycles—reducing cumulative toxicity and minimizing unnecessary hospital visits, ultimately enhancing patients’ quality of life.
Once an RLT is injected, it starts to distribute across the body.
Tumor
Radioactivity remains only in tumor
Radioactivity persists in tumor
